40615-08-5

Usage

Uses

Used in Pharmaceutical Industry:
1-ISOQUINOLIN-1-YLMETHANAMINE DIHYDROCHLORIDE is used as a potential therapeutic agent for neurological disorders due to its neuroprotective and anti-inflammatory properties. It is being studied for its ability to protect neurons from damage and reduce inflammation in the brain, which could be beneficial in treating various neurological conditions.
Used in Addiction Treatment:
1-ISOQUINOLIN-1-YLMETHANAMINE DIHYDROCHLORIDE is used as a potential treatment for addiction and substance abuse. Its ability to modulate the brain's reward system and reduce cravings may make it a valuable tool in helping individuals overcome addiction and maintain sobriety.
Used in Drug Formulation:
1-ISOQUINOLIN-1-YLMETHANAMINE DIHYDROCHLORIDE is used as a pharmaceutical ingredient in drug formulations due to its enhanced solubility in the dihydrochloride salt form. This improved solubility allows for better absorption and bioavailability of the compound, potentially leading to more effective treatments.

InChI:InChI=1/C10H10N2/c11-7-10-9-4-2-1-3-8(9)5-6-12-10/h1-6H,7,11H2

Upstream product

• 1198-30-7 1-isoquinolinecarbonitrile 
• 119-65-3 isoquinoline 
• 1532-72-5 isoquinoline N-oxide 
• 27311-65-5 1-chloromethyl-isoquinoline 
• 1355450-11-1 N-(1-isoquinolylmethyl)phthalimide 
• 123026-29-9 imidazolyl-1-isoquinolinylmethanone 
• 1436-44-8 isoquinoline-1-carboxamide 
• 486-73-7 1-isoquinolinecarboxylic acid 

Downstream Products

• 1173997-55-1 C₁₇H₁₅N₃S 
• 1355450-12-2 tris(1-isoquinolylmethyl)amine 
• 79848-93-4 N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide 
• 135526-78-2 (-)-Praziquantel 
• 60567-47-7 (S)-1-[(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)]cyclohexanecarboxylic acid amide 
• 765915-89-7 N-[(R)-1-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)]cyclohexanecarboxylic acid amide 
• 19382-37-7 3-phenylimidazo<5,1-a>isoquinoline 
• 19382-36-6 N-(isoquinolin-1-ylmethyl)benzamide 
• 1354688-24-6 (acetate)Cu(bis(1-isoquinolylcarbonyl)amide) 
• 1214174-14-7 C₂₀H₁₆N₂O₂ 
• 1025965-13-2 C₂₈H₂₂N₄O 

Relevant academic research and scientific papers

MANUFACTURING METHOD OF OPTICAL ACTIVE SECONDARY ALCOHOL

PROBLEM TO BE SOLVED: To provide a method for manufacturing optical active secondary alcohol with high optical purity by hydrogenating a substrate carbonyl compound using a ruthenium complex with a specific optical active diphosphine compound and an amine compound of which synthesis is easy as ligands as a catalyst. SOLUTION: The manufacturing method of optical active secondary alcohol including reacting a substrate carbonyl compound (excluding 3-quinuclidinone, a 3-quinuclidinone derivative having a substituent, and ketone having an aromatic hydrocarbon group and a heterocycle) with hydrogen and/or a hydrogen-donating compound in a presence of a ruthenium complex selected from a compound represented by the following general formula (1) RuXYAB (1) [X and Y are same or different, represent a hydrogen atom or an anionic group, A represents optical active diphosphine represented by the general formula (2), and B represents an amine compound represented by the following general formula (3)]. SELECTED DRAWING: None COPYRIGHT: (C)2019,JPO&INPIT

METHOD FOR THE PRODUCTION OF PRAZIQUANTEL AND PRECURSORS THEREOF

The present invention provides methods of preparing Praziquantel, in particular (R)-Praziquantel and analogues thereof in a stereoselective manner. One method involves asymmetric hydrogenation of the following intermediate compound (I) and subsequent cyclization.

PROCESS FOR PRODUCING OPTICALLY ACTIVE SECONDARY ALCOHOL

[Object] The object of this invention is to provide a method for producing an optically active secondary alcohol at a high optical purity by hydrogenating a substrate carbonyl compound at a high efficiency using as a catalyst a ruthenium complex bearing as a ligand certain optically active diphosphine compound and a readily synthesized amine compound. [Solution] The method of producing an optically active secondary alcohol according to the present invention is characterized in that a substrate carbonyl compound (provided that 3-quinuclidinone, 3-quinuclidinone derivative having a substituent, and a ketone having an aromatic hydrocarbon group and a heterocycle are excluded) is reacted with hydrogen and/or a hydrogen donating compound in the presence of a ruthenium complex selected from the compounds expressed by following general formula (1) RuXYAB (1) [in the general formula (1), X and Y are the same or different from each other and denote a hydrogen atom or an anionic group, A denotes an optically active diphosphine expressed by the general formula (2), B denotes an amine compound expressed by following general formula (3)].

Triflic anhydride mediated synthesis of imidazo[1,5-a]azines

Imidazo[1,5-a]azines are synthesized in moderate to excellent yields using a mild cyclodehydration/aromatization reaction triggered by the use of triflic anhydride (Tf2O) and 2-methoxypyridine (2-MeOPyr). Various substitution patterns and functional groups were found to be compatible under the optimized conditions. In addition, a 5-bromo-3-aryl derivative was also shown to be active in a Sonogashira cross-coupling and direct arylation reactions. A tertiary amide was compatible as a substrate leading to the synthesis of an imidazo[1,5-a]pyridinium triflate.

Zinc-specific fluorescent response of tris(isoquinolylmethyl)amines (isoTQAs)

Isoquinoline-based tetradentate ligands with C3-symmetry, tris(1- or 3-isoquinolylmethyl)amine (1- or 3-isoTQA), have been prepared and their zinc-induced fluorescence enhancement was investigated. Upon excitation at 324 nm, 1-isoTQA shows very weak fluorescence (β = ～0.003) in DMF/H2O (1/1) solution. In the presence of zinc ion, 1-isoTQA exhibits fluorescence increase (β = 0.041) at 359 and 470 nm. This fluorescence enhancement at 470 nm is specific for zinc. However, 3-isoTQA exhibited a smaller fluorescence enhancement upon zinc complexation (β = 0.017, λem = 360 and 464 nm) compared with 1-isoTQA. Crystal structures of zinc complexes of isoTQAs demonstrate the diminished steric crowding and shorter Zn-Naromatic distances compared with isoTQENs (N,N,N′,N′-tetrakis(isoquinolylmethyl)ethylenediamines) leads to a higher fluorescent response toward zinc relative to cadmium.

Copper(II) acetate mediated conversion of ortho aminomethyl substituted isoquinolines to bis(isoquinolylcarbonyl)amides

An ethanolic solution of ortho aminomethyl substituted isoquinolines, on stirring in air with half equivalent of [Cu(OAc)2(H2O)], afforded [Cu(1-L)(OAc)] (1) and [Cu(3-L)(OAc)] (2) {1-L = bis(1- isoquinolylcarbonyl)amide ion and 3-L = bis(3-isoquinolylcarbonyl)amide ion}. This reaction involves the oxidation of a methylene group and the formation of a bond between nitrogen and carbon in N-C(O) through coupling. The free ligands can be isolated as crystalline solids from compounds 1-2, by extrusion of the Cu2+ ion using EDTA2-. The molecular structure of 1·2.5H2O has been established and the copper(II) center has a pseudo square-planar N3O environment. A packing diagram shows the existence of a centrosymmetric dimer in which two copper centers are intermolecularly linked by the O2 atom of the amide function, leading to a Cu2O2 unit.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and are selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein T is selected from the group consisting of D, E, F, G, H, I, and J are independently N or CY 1, provided that the number of such variables D, E, F, G, H, I, and J representing N is 0, 1, or 2; K, L, M and Q are independently NH or CY1Y2, provided that the number of such variables D, E, F, K, L, M, and Q representing N is 0, 1, or 2; Y1 and Y2 are independently selected from the group consisting of hydrogen, C1-4 alkyl, halogen, anino, or hydroxy; A is